Antibody-dependent enhancement of severe dengue disease in humans

Science

Volumn 358, Issue 6365, 2017, Pages 929-932

  Katzelnick, Leah C ^a   Gresh, Lionel ^b   Halloran, M Elizabeth ^c,d   Mercado, Juan Carlos ^e   Kuan, Guillermina ^e   Gordon, Aubree ^f   Balmaseda, Angel ^e   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sustainable Sciences Institute   (Nicaragua)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e Ministry of Health   (Nicaragua)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; VIRUS ANTIBODY;

ANTIBODY; DENGUE FEVER; HEALTH RISK; IMMUNE RESPONSE; LABORATORY METHOD; PATHOGENICITY; STATISTICAL ANALYSIS; SYMPTOM; VACCINE; VIRUS;

ADOLESCENT; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DENGUE; DISEASE SEVERITY; HUMAN; IMMUNE SYSTEM; INFECTION RISK; MAJOR CLINICAL STUDY; NICARAGUA; PATHOGENESIS; PRIORITY JOURNAL; BLOOD; COHORT ANALYSIS; FEMALE; IMMUNOLOGY; MALE; PRESCHOOL CHILD; VIROLOGY;

NICARAGUA;

ANIMALIA; DENGUE VIRUS GROUP;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE;

EID: 85033583899     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aan6836     Document Type: Article

References (33)

1. S. Bhatt et al., Nature 496, 504–507 (2013).
2. World Health Organization (WHO)/Special Programme for Research and Training in Tropical Diseases (TDR), “Dengue: Guidelines for diagnosis, treatment, prevention and control” (WHO, 2009).
3. WHO, “Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control” (WHO, ed. 2, 1997).
4. N. Sangkawibha et al., Am. J. Epidemiol. 120, 653–669 (1984).
5. M. G. Guzman, E. Harris, Lancet 385, 453–465 (2015).
6. T. T. Wang et al., Science 355, 395–398 (2017).
7. P. R. Beatty et al., Sci. Transl. Med. 7, 304ra141 (2015).
8. R. M. Zellweger, T. R. Prestwood, S. Shresta, Cell Host Microbe 7, 128–139 (2010).
9. K. L. Williams et al., PLOS Pathog. 9, e1003157 (2013).
10. S. R. Hadinegoro et al., N. Engl. J. Med. 373, 1195–1206 (2015).
11. N. M. Ferguson et al., Science 353, 1033–1036 (2016).
12. C. P. Simmons et al., J. Infect. Dis. 196, 416–424 (2007).
13. T. N. Chau et al., J. Infect. Dis. 198, 516–524 (2008).
14. T. N. Chau et al., J. Infect. Dis. 200, 1893–1900 (2009).
15. S. C. Kliks, S. Nimmanitya, A. Nisalak, D. S. Burke, Am. J. Trop. Med. Hyg. 38, 411–419 (1988).
16. H. Clapham et al., PLOS Negl. Trop. Dis. 9, e0004262 (2015).
17. K. Laoprasopwattana et al., J. Infect. Dis. 192, 510–519 (2005).
18. D. H. Libraty et al., PLOS Med. 6, e1000171 (2009).
19. S. C. Kliks, A. Nisalak, W. E. Brandt, L. Wahl, D. S. Burke, Am. J. Trop. Med. Hyg. 40, 444–451 (1989).
20. G. Kuan et al., Am. J. Epidemiol. 170, 120–129 (2009).
21. See supplementary materials.
22. R. J. Fernández, S. Vázquez, Mem. Inst. Oswaldo Cruz 85, 347–351 (1990).
23. R. de Alwis et al., PLOS Pathog. 10, e1004386 (2014).
24. A. Balmaseda et al., Trop. Med. Int. Health 11, 935–942 (2006).
25. T. M. Therneau, A Package for Survival Analysis in S, version 2.38 (2015); https://CRAN.R-project.org/package=survival.
26. F. Narvaez et al., PLOS Negl. Trop. Dis. 5, e1397 (2011).
27. N. Alexander et al., Trop. Med. Int. Health 16, 936–948 (2011).
28. L. Meira-Machado, C. Cadarso-Suárez, F. Gude, A. Araújo, Comput. Math. Methods Med. 2013, 745742 (2013).
29. L. C. Katzelnick, M. Montoya, L. Gresh, A. Balmaseda, E. Harris, Proc. Natl. Acad. Sci. U.S.A. 113, 728–733 (2016).
30. D. Buddhari et al., PLOS Negl. Trop. Dis. 8, e3230 (2014).
31. S. A. Plotkin, P. B. Gilbert, Clin. Infect. Dis. 54, 1615–1617 (2012).
32. E. Simon-Lorière et al., Sci. Transl. Med. 9, eaal5088 (2017).
33. L. C. Katzelnick, E. Harris; Participants in the Summit on Dengue Immune Correlates of Protection, Vaccine 35, 4659–4669 (2017).